Targeting the IL-17/IFN-Î³ axis as a potential new clinical therapy for type 1 diabetes.

Marwaha, Ashish K; Tan, Sara; Dutz, Jan P

Marwaha, Ashish K; Tan, Sara; Dutz, Jan P.

Afiliação

Marwaha AK; Department of Dermatology and Skin Science, Faculty of Medicine, Child and Family Research Institute, The University of British Columbia, Vancouver, British Columbia, Canada.
Tan S; Department of Dermatology and Skin Science, Faculty of Medicine, Child and Family Research Institute, The University of British Columbia, Vancouver, British Columbia, Canada.
Dutz JP; Department of Dermatology and Skin Science, Faculty of Medicine, Child and Family Research Institute, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: dutz@interchange.ubc.ca.

Clin Immunol ; 154(1): 84-9, 2014 Sep.

Article em En | MEDLINE | ID: mdl-24947953

Assuntos

Diabetes Mellitus Tipo 1/terapia; Sistemas de Liberação de Medicamentos; Interferon gama/imunologia; Interleucina-17/imunologia; Anticorpos Monoclonais Humanizados/uso terapêutico; Diabetes Mellitus Tipo 1/fisiopatologia; Humanos; Linfócitos T/imunologia; Ustekinumab

Palavras-chave

Clinical trial; IFN-Î³;; IL-17;; Stelara;; Type 1 diabetes;; Ustekinumab;

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon gama / Sistemas de Liberação de Medicamentos / Interleucina-17 / Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google